• RSS
    • Twitter
    • Facebook
    • Email
    • LinkedIn
    Partner Therapeutics
    • About PTx
      • Leadership
      • Compliance
      • Business Development
      • Careers
      • News
    • Products
      • LEUKINE® (Sargramostim)
    • Research
      • Our Approach
      • Clinical Trials
      • Publications
      • COVID-19
    • Medical Info
      • Medical Inquiries
    • Contact Us
      • Contact Information
      • Lexington, MA
      • Lynnwood, WA

    Sargramostim Clinical Trials

    Infectious Disease

    COVID-19

    Sargramostim Use in COVID-19 to Recover Patient Health (SCOPE)

    Study of Sargramostim in Patients With COVID-19 (iLeukPulm)

    Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)

    Using GM-CSF as a Host Directed Therapeutic Against COVID-19

    A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19) (Japan)

    Cancer

    Hematologic Malignancies

    GM-CSF With Post-Transplant Cyclophosphamide

    Solid Tumors

    Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors (SALIENT)

    Melanoma

    Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

    Biliary Cancer

    Pembrolizumab and GM-CSF in Biliary Cancer

    Lung Cancer

    Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advanced Non-small Cell Lung Cancer

    Neurology

    Parkinson’s disease

    Biomarker Assessments of Leukine During Treatment of Parkinson’s Disease

    Alzheimer’s Disease

    Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer’s Disease

    Vascular

    Peripheral Arterial Disease

    Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (GPAD-3)

     

    Note: Not all clinical trials including sargramostim are listed.

     
     

    Latest News

    •  

      Partner Therapeutics Announces Publication of a Retrospective Cohort Review of 15 LEUKINE® Treated Patients with Pediatric Malignancies and Invasive Fungal Disease Refractory to Antifungal Therapy

      ...

    •  

      Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down Syndrome and Normal Aging

      ...

    •  

      Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine® to Treat Sulfur Mustard Gas (HD) Exposure

      ...


    Join Our Team

    Partner Therapeutics (PTx) is a commercial biotech committed to improving the lives of patients with cancer and other serious diseases. We're looking for passionate professionals to join us with expertise that spans the biopharma value chain.

     

    View Current Openings
      © 2020 Partner Therapeutics, Inc.
    • Home
    • News
    • Privacy Policy
    • Terms of Use